Literature DB >> 1697461

A blocking monoclonal antibody to endothelial-leukocyte adhesion molecule-1 (ELAM1).

C Benjamin1, I Dougas, G Chi-Rosso, S Luhowskyj, M Rosa, B Newman, L Osborn, C Vassallo, C Hession, S Goelz.   

Abstract

ELAM1 is a leukocyte adhesion molecule induced on human umbilical vein endothelial cells (HUVECs) by inflammatory cytokines. Balb/C mice were immunized with COS cells transiently expressing cell-surface ELAM1 after transfection with ELAM1 cDNA. After fusion, ELAM1-specific monoclonal antibodies (Mabs) were identified by selective adhesion to ELAM1-expressing, but not control, CHO cells, and to cytokine-treated but not untreated HUVECs. One Mab, designated BB11, binds to and immunoprecipitates ELAM1 expressed on HUVECs, COS and CHO cells. BB11 blocks the interaction of ELAM1 with human PMN, the human myelomonocytic cell line HL60, and the human colon carcinoma line HT29.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1697461     DOI: 10.1016/0006-291x(90)91400-m

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  23 in total

Review 1.  Alpha 4-integrin-dependent emigration of monocytes.

Authors:  H E Chuluyan; A C Issekutz
Journal:  Springer Semin Immunopathol       Date:  1995

2.  IL-17A potentiates TNFα-induced secretion from human endothelial cells and alters barrier functions controlling neutrophils rights of passage.

Authors:  Markus H Bosteen; Katerina Tritsaris; Anker J Hansen; Steen Dissing
Journal:  Pflugers Arch       Date:  2013-09-27       Impact factor: 3.657

3.  Mechanisms of eosinophil adherence to cultured vascular endothelial cells. Eosinophils bind to the cytokine-induced ligand vascular cell adhesion molecule-1 via the very late activation antigen-4 integrin receptor.

Authors:  A Dobrina; R Menegazzi; T M Carlos; E Nardon; R Cramer; T Zacchi; J M Harlan; P Patriarca
Journal:  J Clin Invest       Date:  1991-07       Impact factor: 14.808

4.  Attenuation of colitis in the cotton-top tamarin by anti-alpha 4 integrin monoclonal antibody.

Authors:  D K Podolsky; R Lobb; N King; C D Benjamin; B Pepinsky; P Sehgal; M deBeaumont
Journal:  J Clin Invest       Date:  1993-07       Impact factor: 14.808

5.  Leptospira icterohemorrhagiae and leptospire peptidolgycans induce endothelial cell adhesiveness for polymorphonuclear leukocytes.

Authors:  A Dobrina; E Nardon; E Vecile; M Cinco; P Patriarca
Journal:  Infect Immun       Date:  1995-08       Impact factor: 3.441

6.  Borrelia burgdorferi upregulates expression of adhesion molecules on endothelial cells and promotes transendothelial migration of neutrophils in vitro.

Authors:  T J Sellati; M J Burns; M A Ficazzola; M B Furie
Journal:  Infect Immun       Date:  1995-11       Impact factor: 3.441

7.  The ELAM ligand fucosyltransferase, ELFT, directs E-selectin binding to a secreted scaffold protein: a method to produce and purify large quantities of specific carbohydrate structures.

Authors:  W Meier; D R Leone; K Miatkowski; R Lobb; S E Goelz
Journal:  Biochem J       Date:  1993-08-15       Impact factor: 3.857

8.  Endotoxin activation of endothelium for polymorphonuclear leucocyte transendothelial migration and modulation by interferon-gamma.

Authors:  A C Issekutz; N Lopes
Journal:  Immunology       Date:  1993-08       Impact factor: 7.397

9.  Polymorphonuclear leucocyte migration through human dermal fibroblast monolayers is dependent on both beta 2-integrin (CD11/CD18) and beta 1-integrin (CD29) mechanisms.

Authors:  J X Gao; A C Issekutz
Journal:  Immunology       Date:  1995-07       Impact factor: 7.397

10.  Increased binding of synovial T lymphocytes from rheumatoid arthritis to endothelial-leukocyte adhesion molecule-1 (ELAM-1) and vascular cell adhesion molecule-1 (VCAM-1).

Authors:  A A Postigo; R Garcia-Vicuña; F Diaz-Gonzalez; A G Arroyo; M O De Landázuri; G Chi-Rosso; R R Lobb; A Laffon; F Sánchez-Madrid
Journal:  J Clin Invest       Date:  1992-05       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.